The safety profile of biologic agents in comparison with non-biologic systemic agents, and topical compounds in the management of psoriasis - a 30-month prospective, observational cohort study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F21%3A43922214" target="_blank" >RIV/00216208:11120/21:43922214 - isvavai.cz</a>
Alternative codes found
RIV/62156489:43110/21:43920303 RIV/00216208:11110/21:10431936 RIV/00064211:_____/21:W0000007 RIV/00216208:11130/21:10431936
Result on the web
<a href="https://doi.org/10.1111/ijcp.14915" target="_blank" >https://doi.org/10.1111/ijcp.14915</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/ijcp.14915" target="_blank" >10.1111/ijcp.14915</a>
Alternative languages
Result language
angličtina
Original language name
The safety profile of biologic agents in comparison with non-biologic systemic agents, and topical compounds in the management of psoriasis - a 30-month prospective, observational cohort study
Original language description
BACKGROUND: Although biologic agents are very effective, solid data proving they are safer than other therapies in psoriasis are still lacking. METHODS: A total of 289 psoriatic patients were followed for 30 months; of which number 118 were treated with topical agents alone, 112 received biologic agents, and the remaining 59 patients were on non-biologic systemic agents. The rates of adverse events in these groups were recorded and statistically analyzed. RESULTS: Patients treated with biologic agents had higher rates of adverse events (p=0.017), including overall infections (p=0.003), respiratory infections (p<0.001), renal, urinary (p<0.001), musculoskeletal, connective tissue (p<0.001, and p=0.021) and oral cavity-related (p=0.046) disorders. Except for the incidence of infections, all the above adverse events occurred more often in our study than in clinical trials. The occurrence of serious adverse events was p=0.066, with the incidence of serious infections being p=0.164. Unlike patients on topical therapy and non-biologic systemic agents, patients treated with biologic agents were forced to discontinue their therapies (p=0.001). The Psoriasis Area Severity Index (PASI) and Body Surface Area (BSA) scores were the lowest among patients on biologic agents. CONCLUSION: While biologic agents were the most effective therapies, they were associated with higher rates of treatment discontinuation and adverse events in comparison with other forms of therapy.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30216 - Dermatology and venereal diseases
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
International Journal of Clinical Practice
ISSN
1368-5031
e-ISSN
—
Volume of the periodical
75
Issue of the periodical within the volume
12
Country of publishing house
GB - UNITED KINGDOM
Number of pages
11
Pages from-to
"e14915"
UT code for WoS article
000703754200001
EID of the result in the Scopus database
2-s2.0-85116488777